Skip to main content

Advertisement

Figure 6 | Molecular Cancer

Figure 6

From: P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines

Figure 6

Combination studies of standard therapies with P276-00. P276-00 has synergistic anti MCL activity when combined with bortezomib at 100 nM and doxorubicin at 1000 nM. Combination index (CI) was calculated using CompuSyn software. Data for (A) Bortezomib (100 nmol/L) and (B) Doxorubicin (1 μmol/L) are represented, with synergism noted at given concentration of P276-00 and CI of less than 1.

Back to article page